{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:23:35Z","timestamp":1778617415387,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Government of Japan Ministry of Health Labour and Welfare","doi-asserted-by":"publisher","award":["24\\u202FK10944"],"award-info":[{"award-number":["24\\u202FK10944"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.clim.2025.110470","type":"journal-article","created":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T18:18:58Z","timestamp":1740939538000},"page":"110470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["JAK inhibitor ameliorates inflammatory bowel disease in a patient with IKZF1 haploinsufficiency"],"prefix":"10.1016","volume":"274","author":[{"given":"Shota","family":"Inoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaatsu","family":"Ikai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusuke","family":"Nambu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Tagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Kyushiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayoko","family":"Ichimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Isoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Kanegane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohsuke","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2025.110470_bb0005","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1074-7613(00)80269-1","article-title":"Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation","volume":"5","author":"Wang","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2025.110470_bb0010","first-page":"132","article-title":"Ikaros in B cell development and function, world","volume":"2","author":"Sellars","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2025.110470_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10875-020-00936-x","article-title":"IKAROS-associated diseases in 2020: Genotypes, phenotypes, and outcomes in primary immune deficiency\/inborn errors of immunity","volume":"41","author":"Kuehn","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2025.110470_bb0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jaci.2016.09.029","article-title":"Abnormal hematopoiesis and autoimmunity in human subjects with germline IKZF1 mutations","volume":"140","author":"Hoshino","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2025.110470_bb0025","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.iac.2020.04.004","article-title":"IKAROS family zinc finger 1-associated diseases in primary immunodeficiency patients","volume":"40","author":"Nunes-Santos","year":"2020","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.clim.2025.110470_bb0030","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3389\/fimmu.2019.00568","article-title":"Assessing the functional relevance of variants in the IKAROS family zinc finger protein 1 (IKZF1) in a cohort of patients with primary immunodeficiency","volume":"10","author":"Eskandarian","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2025.110470_bb0035","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi7160","article-title":"Gain-of-function IKZF1 variants in humans cause immune dysregulation associated with abnormal T\/B cell late differentiation","volume":"7","author":"Hoshino","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.clim.2025.110470_bb0040","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.clim.2025.110470_bb0045","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.clim.2025.110470_bb0050","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2217\/imt-2023-0116","article-title":"The role of filgotinib in ulcerative colitis and Crohn\u2019s disease","volume":"16","author":"Fanizza","year":"2024","journal-title":"Immunotherapy"},{"key":"10.1016\/j.clim.2025.110470_bb0055","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-020-01439-0","article-title":"Filgotinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.clim.2025.110470_bb0060","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.gastha.2022.05.011","article-title":"Histopathological features of monogenic inflammatory bowel disease: subanalysis of systematic review","volume":"1","author":"Nambu","year":"2022","journal-title":"Gastro Hep. Adv."},{"key":"10.1016\/j.clim.2025.110470_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/ueg2.12686","article-title":"Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: a post hoc analysis from the SELECTION study","author":"Schreiber","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.clim.2025.110470_bb0070","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/apt.17961","article-title":"Efficacy and safety of filgotinib for ulcerative colitis: a real-world multicenter retrospective study in Japan","volume":"59","author":"Akiyama","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.clim.2025.110470_bb0075","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/apt.18158","article-title":"Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study","volume":"60","author":"Feagan","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.clim.2025.110470_bb0080","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2025.110470_bb0085","doi-asserted-by":"crossref","first-page":"e653","DOI":"10.1016\/j.cgh.2021.03.021","article-title":"A systematic review of monogenic inflammatory bowel disease","volume":"20","author":"Nambu","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2025.110470_bb0090","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41575-023-00838-4","article-title":"Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards","volume":"20","author":"Uhlig","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2025.110470_bb0095","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1182\/blood-2019-127209","article-title":"Targeting activated signaling pathways for the treatment of IKZF1-deleted B lymphoblastic leukemia","volume":"134","author":"Gupta","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clim.2025.110470_bb0100","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.immuni.2024.07.010","article-title":"Transcription factor Ikzf1 associates with Foxp3 to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity","volume":"57","author":"Ichiyama","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2025.110470_bb0105","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.clim.2025.110470_bb0110","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1073\/pnas.91.8.2985","article-title":"Tyrosine kinase JAK1 is associated with the granulocyte-colony-stimulating factor receptor and both become tyrosine-phosphorylated after receptor activation","volume":"91","author":"Nicholson","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.clim.2025.110470_bb0115","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2025.110470_bb0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.clim.2014.10.010","article-title":"Disease specificity of anti-tryptophan hydroxylase-1 and anti-AIE-75 autoantibodies in APECED and IPEX syndrome","volume":"156","author":"Chida","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2025.110470_bb0125","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clim.2011.05.010","article-title":"Autoantibodies to villin occur frequently in IPEX, a severe immune dysregulation, syndrome caused by mutation of FOXP3","volume":"141","author":"Kobayashi","year":"2011","journal-title":"Clin. Immunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625000452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625000452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:03:23Z","timestamp":1778616203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661625000452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":25,"alternative-id":["S1521661625000452"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2025.110470","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK inhibitor ameliorates inflammatory bowel disease in a patient with IKZF1 haploinsufficiency","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2025.110470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110470"}}